Skip to Main Content

Paper Details

The multikinase inhibitor RXDX-105 is effective against neuroblastoma <i>in vitro</i> and <i>in vivo</i>.
Oncotarget
9
2019
13-cis-retinoic acid, BRAF kinases, ERK kinases, MAPK, MEK, Neuroblastoma, RAS, RET, RET kinase, RXDX, RXDX-105, children, extracranial solid tumor, neuroblastoma, neuroblastoma cells, pediatric cancer, tumor, tumors, xenograft tumors
Author NameAffiliation
Pablo TamayoMoores Cancer Center, University of California San Diego
Pablo TamayoMoores Cancer Center, University of California San Diego
Peter T SageUniversity of California San Diego
Peter T SagePeckham Center for Cancer and Blood Disorders, Rady Children's Hospital
Peter T SageMoores Cancer Center, University of California San Diego
  • 1 - 5

Datasets

Release 1.2